Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2003 / Article

Original Article | Open Access

Volume 17 |Article ID 410276 |

Craig C Earle, Olusegun Agboola, Jean Maroun, Lisa Zuraw, Cancer Care Ontario Practice Guidelines Initiative’s Gastrointestinal Cancer Disease Site Group, "The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline", Canadian Journal of Gastroenterology and Hepatology, vol. 17, Article ID 410276, 7 pages, 2003.

The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline

Received26 Jul 2002
Revised10 Dec 2002


BACKGROUND: Pancreatic adenocarcinoma is the fourth most common cause of adult cancer death. About 50% of patients present with metastatic disease, 20% with resectable disease and the remaining 30% of patients are diagnosed with incurable, locally advanced unresectable but nonmetastatic pancreatic cancer.OBJECTIVES: To evaluate the current evidence regarding treatment of incurable, locally advanced, unresectable but nonmetastatic pancreatic cancer and produce an evidence-based practice guideline.METHODS: A systematic review of the literature was performed. The MEDLINE, CANCERLIT, and Cochrane Library databases were searched using the following medical subject heading search terms: ‘pancreatic neoplasms’, ‘chemotherapy, adjuvant’, ‘radiotherapy’, ‘immunotherapy’, combined with the text words: ‘chemotherapy’, ‘radiotherapy’, ‘radiation’, ‘immunotherapy’, combined with terms for the following study designs or publication types: practice guidelines, meta-analyses and randomized controlled trials. The Physician Data Query clinical trials database and the proceedings of the annual meetings of the American Society of Clinical Oncology (1996 to 2001) and the American Society for Therapeutic Radiology and Oncology (1999 to 2001) were searched for reports of new or ongoing trials. Relevant literature was selected and reviewed independently, and the reference lists from these sources were searched for additional trials. Interpretation of evidence was resolved by consensus.RESULTS: Eight randomized trials were obtained that met the inclusion criteria.CONCLUSIONS: Recommendations are to offer combined chemotherapy and radiotherapy to suitable patients. The preferred chemotherapeutic agent to combine with radiotherapy is bolus or infusional 5-fluorouracil, but the optimal mode and duration of 5-fluorouracil delivery is unclear. Chemotherapy alone with gem-citabine is an acceptable alternative.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.